- What Are Antibody-drug Conjugates?
- AACR D3 Offered a Peek Into the Cancer Drug Pipeline, Innovative AI Tools, and More
- From the Bench, AACR D3 2026: Emerging Therapeutic Strategies to Inhibit KRAS, Enhance ADCs, and Tackle Resistance
- What Is CAR T-cell Therapy?
- Editors’ Picks, July 2026: AI-powered Pancreatic Proteomics, Sex-based Immune Differences, and More
- Cancer Today’s Summer 2026 Issue: Using Patient-reported Outcomes to Address Side Effects, Preventing Graft-versus-host Disease, and More
- Inaugural AACR D3 Opens With Insights From Leaders Across Drug Discovery and Development
- The AACR Rare Cancers Initiative: Uniting Researchers, Undoing Barriers, and Unleashing Progress
- From Treatment to Prevention: How Vaccines Are Reshaping the Fight Against Pancreatic Cancer
- Catching the Drift: How Wildfire Smoke Plumes May Increase Cancer Risk
- Cancer Researchers Explain How OMB’s Proposed Changes to Federal Grantmaking Will Cause Delays, Reduce Transparency, and Undermine Merit-based Processes
- Chris Baccash: A Brain Cancer Survivor Who Is Cycling to Make a Difference
- From Discovery to Clinical Impact: AACR Special Conference Captured the Spectrum of Lymphoma Research
- FDA Approvals in Oncology: April-June 2026
- Editors’ Picks, June 2026: Preventing Colorectal Cancer, Targeting Neural Cross-talk to Stop Glioblastoma Recurrence, and More
